Vivek Subbiah, MD of MD Anderson Cancer Center discusses the impact of his study of vemurafenib in NSCLC patients on clinical practice and future clinical research. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 9074: Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600mutation.
Advertisement